Complex percutaneous coronary intervention in patients unable to undergo coronary artery bypass grafting during the COVID-19 pandemic: insights from the UK-ReVasc Registry.

Autor:	Kite TA; Department of Cardiovascular Sciences and the NIHR Leicester Biomedical Research Center, Glenfield Hospital, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK. Email: tom.kite@nhs.net., Chase A; College of Medicine, Swansea University, Morriston Regional Heart Center, Swansea, UK., Owens CG; Department of Cardiology, Royal Victoria Hospital, Belfast, UK., Shaukat A; West of Scotland Heart and Lung Center, Golden Jubilee National Hospital, Glasgow, UK., Mozid AM; Leeds General Infirmary, Leeds, UK., O'Kane P; Dorset Heart Center, Royal Bournemouth Hospital, Bournemouth, UK., Routledge H; Worcestershire Royal Hospital, Worcester, UK., Perera D; BHF Center of Research Excellence and NIHR Biomedical Research Center at King's College London, UK., Jain AK; Barts Heart Center St Bartholomew's Hospital, Barts and the London School of Medicine and Dentistry, London, UK., Palmer N; Liverpool Heart and Chest Hospital, Liverpool, UK., Hoole SP; Department of Cardiology, Royal Papworth Hospital, Cambridge, UK., Egred M; Freeman Hospital, Newcastle University, Translational and Clinical Research Institute, Newcastle-Upon-Tyne, UK., Sinha MK; Salisbury NHS Foundation Trust, Salisbury, UK., Cahill TJ; Oxford Heart Center, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Anantharam B; Portsmouth Hospitals University NHS Trust, Portsmouth, UK., Byrne J; Department of Cardiology, King's College NHS Foundation Trust, London, UK., Morris PD; Department of Cardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK., Kean S; Robertson Center for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Sabra A; College of Medicine, Swansea University, Morriston Regional Heart Center, Swansea, UK., Aetesam-Ur-Rahman M; Department of Cardiovascular Sciences and the NIHR Leicester Biomedical Research Center, Glenfield Hospital, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK., Mailey J; Department of Cardiology, Royal Victoria Hospital, Belfast, UK., Demir O; BHF Center of Research Excellence and NIHR Biomedical Research Center at King's College London, UK; Guy's and St Thomas' Hospital NHS Foundation Trust, UK., Mouyis K; Barts Heart Center St Bartholomew's Hospital, Barts and the London School of Medicine and Dentistry, London, UK., Abdalwahab A; Freeman Hospital, Newcastle University, Translational and Clinical Research Institute, Newcastle-Upon-Tyne, UK., Terentes-Printzios D; Oxford Heart Center, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Kanyal R; Department of Cardiology, King's College NHS Foundation Trust, London, UK., Curzen N; Faculty of Medicine, University of Southampton and Wessex Cardiac Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Berry C; BHF Glasgow Cardiovascular Research Center, University of Glasgow, UK; Golden Jubilee National Hospital, Clydebank, UK., Gershlick AH; Department of Cardiovascular Sciences and the NIHR Leicester Biomedical Research Center, Glenfield Hospital, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK., Ladwiniec A; Department of Cardiovascular Sciences and the NIHR Leicester Biomedical Research Center, Glenfield Hospital, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Jazyk:	angličtina
Zdroj:	The Journal of invasive cardiology [J Invasive Cardiol] 2024 Mar 06. Date of Electronic Publication: 2024 Mar 06.
DOI:	10.25270/jic/24.00030
Abstrakt:	Objectives: Cardiac surgery for coronary artery disease was dramatically reduced during the first wave of the COVID-19 pandemic. Many patients with disease ordinarily treated with coronary artery bypass grafting (CABG) instead underwent percutaneous coronary intervention (PCI). We sought to describe 12-month outcomes following PCI in patients who would typically have undergone CABG. Methods: Between March 1 and July 31, 2020, patients who received revascularization with PCI when CABG would have been the primary choice of revascularization were enrolled in the prospective, multicenter UK-ReVasc Registry. We evaluated the following major adverse cardiovascular events at 12 months: all-cause mortality, myocardial infarction, repeat revascularization, stroke, major bleeding, and stent thrombosis. Results: A total of 215 patients were enrolled across 45 PCI centers in the United Kingdom. Twelve-month follow up data were obtained for 97% of the cases. There were 9 deaths (4.3%), 5 myocardial infarctions (2.4%), 12 repeat revascularizations (5.7%), 1 stroke (0.5%), 3 major bleeds (1.4%), and no cases of stent thrombosis. No difference in the primary endpoint was observed between patients who received complete vs incomplete revascularization (residual SYNTAX score £ 8 vs > 8) (P = .22). Conclusions: In patients with patterns of coronary disease in whom CABG would have been the primary therapeutic choice outside of the pandemic, PCI was associated with acceptable outcomes at 12 months of follow-up. Contemporary randomized trials that compare PCI to CABG in such patient cohorts may be warranted.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu